Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Investor Presentation (January 2017)

27 slides from Lytix Biopharma ASA's investor presentation, January 2017

  1. Slide 1: Lytix Biopharma - Developing novel cancer immunotherapies

    Lytix Biopharma - Developing novel cancer immunotherapies Investor Presentation , January 2017

  2. Slide 2: Lytix Biopharma – Developing novel cancer immunotherapy

    2 Lytix Biopharma – Developing novel cancer immunotherapy  Vision – leading R&D company in the field of cancer immunotherapy  Private R&D focused company based in Oslo  Founded in Tromsö 2003 by Professors John Sigurd Svendsen and Öystein Rekdal  Technology platform derived from research on host

  3. Slide 3: LTX-315 – first-in-class oncolytic peptide immunotherapy

    3 LTX-315 – first-in-class oncolytic peptide immunotherapy • LTX-315 makes cold tumors hot and responsive to immune checkpoint Inhibitors (ICIs) by releasing Unique an extended range of tumor specific antigens product • Strong pre-clinical anticancer activity and increased efficacy with ICIs • Ideal

  4. Slide 4: The Nordic landscape of immuno oncology

    4 The Nordic landscape of immuno oncology  The competitive landscape is rapidly changing, with several different compounds currently being tested in target indications  The companies below have developed different technologies to fight cancer –the real race is abut finding successful combinations

  5. Slide 5: Cancer remains a major medical need

    5 Cancer remains a major medical need Sales of cancer drugs 2015-2022  Largest therapeutic area with 11% of total drug sales  Cancer incidence is expected to grow – Every year, 14 million people are diagnosed with 200 cancer 180  Main pillars of therapy 160 140 – Surgery, radiation, chemo, hormon

  6. Slide 6: Complex diseases require dynamic treatments

    6 Complex diseases require dynamic treatments Cancer immuno-therapy  The role of the immune system is to defend the body against threats e.g. bacteria, cancer  The immune system works in a variety of ways  Cancers hide and constantly transform to trick the immune system resulting in a constant “p

  7. Slide 7: ICIs – the first wave in cancer immunotherapy

    7 ICIs – the first wave in cancer immunotherapy  With ICI’s, immune oncology has taken center stage in the pharmaceutical industry becoming an attractive oncology segment Yervoy (BMS) Keytruda (MSD) Tecentriq (Roche/Genente ch 2011 2012 2013 2014 2015 2016 2017 2018 2019 Durvalumab (AstraZeneca) Av

  8. Slide 8: ICIs – a paradigm shift in cancer treatment

    8 ICIs – a paradigm shift in cancer treatment Next wave is to develop combinations ICI’s: significant progress but no silver bullit  Checkpoint Inhibitors have revolutionised cancer treatment • The success of immunotherapies has changed the way cancers today representing the new backbone of cancer

  9. Slide 9: ICI’s allow T-cells to attack cancer by removing the brakes

    9 ICI’s allow T-cells to attack cancer by removing the brakes ICI’s Tumor specific Increase the activity of T-cells = T-cell activation Removing the brakes

  10. Slide 10: ICIs: Data indicates efficacy only in ”hot” tumors

    10 ICIs: Data indicates efficacy only in ”hot” tumors Few effector T cells  ASCO/ESMO data confirms most tumours are ”cold”, non-T-cell inflamed, lacking effector cells (CD8+)  ICIss require a T-cell inflamed tumor microenvironment for efficacy (”hot” tumor)  Major unmet clinical need – optimisin

  11. Slide 11: LTX-315 enabling checkpoint inhibitors

    11 LTX-315 enabling checkpoint inhibitors ”cold” tumours to ”hot” ICIs does not work in cold tumors LTX-315 will make cold tumors hot and enhance the proportion of cancer patients responding to ICIs Padmanee Sharma, and James P. Allison, Science 2015;348:56-61

  12. Slide 12: LTX-315 unique MoA – making cold tumors hot

    LTX-315 unique MoA – making cold tumors hot LTX-315 releases potent immune stimulants and a broad repertoire of tumor antigens Zhou, Cell Death & Disease 2016. Zhou, Oncotarget 2015. Forveille, Cell Cycle 2015. Eike, Oncotarget, 2015. Camilio, OncoImmunology 2014, Camilio, Cancer Immunol Immunother,

  13. Slide 13: LTX-315 expands T-cell clonality in treated tumors

    LTX-315 expands T-cell clonality in treated tumors Enhances immune responses to tumor antigens  The diversity of T-cell clones is significantly enhanced in LTX- 315 treated tumors versus untreated tumors  Each T-cell clone recognizes different tumor antigenes  LTX-315 induces release of neo-antig

  14. Slide 14: LTX-315 and tumor heterogenity

    LTX-315 and tumor heterogenity  Tumor heterogenity limits the efficacy of therapies  By injecting LTX-315 in multiple lesions a broader and more representative tumor antigen repertoire is presented for T-cells Fig from Jamal-Hanjani, Clin.Cancer Res, 2015

  15. Slide 15: Pre-clinical data: LTX-315 induces systemic immune response

    15 Pre-clinical data: LTX-315 induces systemic immune response Eliminates non-treated tumors 2nd tumor 3rd tumor Control v 1st 2nd 3rd LTX-315 v Days  The effect on distant tumors demonstrates an immediate systemic immune response  Treated animals showed no tumor growth after being re-challenged u

  16. Slide 16: LTX-315: Preclinical synergy with immune checkpoint inhibitors

    16 LTX- 315: Preclinical synergy with immune checkpoint inhibitors  Efficacy of immune checkpoint inhibitors require Anti-CTLA-4 and LTX-315 – inflamed tumor microenvironment – immune responses to neoantigens Placebo  LTX-315 creates LTX-315 Anti-CTLA-4 – inflamed tumor microenvironment Anti-CTLA-

  17. Slide 17: Phase I - LTX-315 anti-tumor activity confirmed in patients

    17 Phase I - LTX-315 anti-tumor activity confirmed in patients Melanoma Patient (inj.lesion) Ongoing open phase 1, typical ph1 patient population, different cancer types, dose escalation, multilesion injections Complete and partial regression of injected lesions • 31% (8/26) of injected lesions Base

  18. Slide 18: Phase I – LTX-315 makes “cold” tumors “hot”

    Phase I – LTX-315 makes “cold” tumors “hot”

  19. Slide 19: Phase I – Patient case report indicating abscopal effect

    Phase I – Patient case report indicating abscopal effect LTX-315 induces SD* after progression on antiPDL1  38 yr female, metastatic adrenocortical Ca (lung,liver peritoneal, bone metastasis) diagnosed in yr 2000  Multiple prior treatments: surgery (primary & met lesions), chemotherapy, radiothera

  20. Slide 20: Clinical development program LTX-315

    20 Clinical development program LTX-315 2015 2016 2017 2018 2019 2020 H1 H2 H1 H2 H1 H2 H1 H2 H1 H2 H1 H2 MONOTHERAPY TRIALS Mixed indications Ph I Single lesion Phase I Multiple lesions Phase I (20) COMBINATION TRIALS FPI. FPI. Interim. LPI data Malignant melanoma (2nd Line) PhI/II Prep. Phase I Pr

  21. Slide 21: Clinical Advisory Board / Scientific Advisory Board

    21 Clinical Advisory Board  Robert Andtbacka, M.D., associate professor in the Division of Surgical Oncology, University of Utah School of Medicine, U.S  Sandra Demaria, M.D., professor of pathology and radiation oncology, Weill Cornell Medical College, NY, U.S  Kevin Harrington, M.D., PhD., prof

  22. Slide 22: Collaboration is an important element in Lytix business strategy

    Collaboration is an important element in Lytix business strategy Harvard University (M. Pittet) • LTX-315`s ability to convert “cold” tumors to “hot” in genetically-engineered murine cancer models Weill Cornell Medicine (Sandra Demaria) • LTX-315 in combination with irradiation in poorly immunogenic

  23. Slide 23: Pipeline

    23 Pipeline PLATFORM PROGRAM LTX-315 Monotherapy All solid tumours Transdermally Malignant melanoma Combination accessible tumors therapy w/ICIs Triple Negative Breast Cancer (TNBC) Undisclosed project ‘’cold to hot’’ Undisclosed indication Deep-seated LTX-401 tumours Deep-seated DTT tumours PRECLIN

  24. Slide 24: Management Team

    24 Management Team Håkan Wickholm, CEO Andrew Saunders, CMO  Extensive senior international leadership and management experience  Trained as a haematologist with 25 years experience in heamato- from AstraZeneca oncology drug development in both clinical practice and industry  Experience from Comm

  25. Slide 25: Board of Directors

    25 Board of Directors Gert W. Munthe, Chairman Knut Eidissen  Founder and Managing Partner of Herkules Capital - a leading Nordic  Owner and managing director of the consulting and investment private equity player. Chairman Pronova Biopharma 2004-2013. company Picasso  Extensive experience from b

  26. Slide 26: Shareholders

    26 Shareholders  Founders and board members control about 30% of Ownership structure, per nov 2016 the shares Shareholders No Shares % NORTH MURRAY AS 160 572 16,0%  The company has about 260 shareholders PICASSO KAPITAL AS 122 189 12,2% TAJ HOLDING AS 78 519 7,8% CARE HOLDING AS 75 230 7,5%  Inc

  27. Slide 27: Investment Case

    27 Investment Case  LTX-315 is a first-in-class powerful oncolytic peptide immunotherapy An emerging  Potential for multiple, high value indications resulting in block buster potential with sales > 1 bn USD immunocology leader  Targeting a rapidly growing and developing market segment attractive

Lytix Biopharma — Investor Presentation (January 2017) on 6ix